"/> Tocris™ dBET6 | B-LABO France

Tocris™ dBET6

Réf. : BL-RE-124784Réf. fabricant : 18726776 5 mg
279,69 € HT

Potent and selective (+)-JQ1 based Degrader (PROTAC™) targeting BET bromodomains, active in vivo

Nom chimique ou matériau
(6 S)-4-(4-Chlorophenyl)-N-[8-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1 H-isoindol-4-yl]oxy]acetyl]amino]octyl]-2,3,9-trimethyl-6 H-thieno[3,2-f][1,2,4 ]triazolo[4,3-a][1,4 ]diazepine-6-acetamide
CAS
1950634-92-0
Quantité
5 mg
Cible
Active Degraders
Formule moléculaire
C42H45ClN8O7S
Marque
Tocris

dBET6 is a potent and selective Degrader (PROTAC™) of BET bromodomains (IC50 = ∽10 nM). dBET6 comprises BET antagonist (+)-JQ1 (Cat.No. 4499) conjugated to a cereblon E3 ubiquitin ligase ligand. Exhibits antitumor activity against T cell acute lymphoblastic leukemia (T-ALL) lines through BRD4 degradation. Induces apoptosis. Reduces leukemic burden in a mouse model of T-ALL. Cell permeable. PROTAC™ is a registered trademark of Arvinas Operations, Inc., and is used under license.

Caractéristiques techniques

MarqueTocris
Réf. B-LABOBL-RE-124784
Réf. fabricant18726776
Nom chimique ou matériau(6 S)-4-(4-Chlorophenyl)-N-[8-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1 H-isoindol-4-yl]oxy]acetyl]amino]octyl]-2,3,9-trimethyl-6 H-thieno[3,2-f][1,2,4 ]triazolo[4,3-a][1,4 ]diazepine-6-acetamide
CAS1950634-92-0
Quantité5 mg
CibleActive Degraders
Formule moléculaireC<sub>42</sub>H<sub>45</sub>ClN<sub>8</sub>O<sub>7</sub>S
Pureté0.98
Une question, une configuration particulière ?
Contactez-nous pour un devis.
Demander un devis 03 65 67 15 79

Produits similaires

Tocris&trade;&nbsp;VU 0134992

Tocris™ VU 0134992

951,38 € HT
Tocris&trade;&nbsp;VU 0134992

Tocris™ VU 0134992

245,13 € HT
Tocris&trade;&nbsp;GSK 1016790A

Tocris™ GSK 1016790A

1 095,00 € HT
Tocris&trade;&nbsp;GSK 1016790A

Tocris™ GSK 1016790A

276,45 € HT